Hartline Investment Corp’s ResMed RMD Stock Holding History

Hartline Investment Corp’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-961	Closed	-$210K	–	112
2023 Q2	$210K	Buy	+961	New	+$214K	0.04%	106

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Hartline Investment Corp's RMD Position: Q3 2023 in Review

Hartline Investment Corp sold out of ResMed (RMD) in Q3 2023, closing a stake of 961 shares — an estimated $210K sold.

Hartline Investment Corp first reported a position in RMD in Q2 2023 and held it in 1 quarter. The position peaked at $210K in Q2 2023. 657 funds tracked by Wall St. Rank hold RMD as of Q3 2023.

Hartline Investment Corp reported no remaining ResMed position as of Q3 2023 after selling out during the quarter.
Hartline Investment Corp sold 961 ResMed shares in Q3 2023, an estimated $210K.
Hartline Investment Corp first reported a position in ResMed in Q2 2023 and held it in 1 quarter.
Hartline Investment Corp's ResMed position peaked at $210K in Q2 2023.
657 funds tracked by Wall St. Rank held ResMed as of Q3 2023.

Based on Hartline Investment Corp's 13F filing for Q3 2023, filed 3 Nov 2023.